These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25713719)

  • 41. A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette-Guérin immunotherapy.
    Poletajew S; Krajewski W; Adamowicz J; Radziszewski P
    Anticancer Drugs; 2019 Jun; 30(5):517-522. PubMed ID: 30870228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW; Shen ZJ; Ding GQ
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
    Brosman SA
    J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
    Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
    Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.
    Pommier JD; Ben Lasfar N; Van Grunderbeeck N; Burdet C; Laouénan C; Rioux C; Pierre-Audigier C; Meybeck A; Choudat L; Benchikh A; Nguyen S; Bouvet E; Yeni P; Yazdanpanah Y; Joly V
    Infect Dis (Lond); 2015; 47(10):725-31. PubMed ID: 26077036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.
    Proctor DD; Chopra S; Rubenstein SC; Jokela JA; Uhl L
    Am J Gastroenterol; 1993 Jul; 88(7):1112-5. PubMed ID: 8317415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.
    Bisiaux A; Thiounn N; Timsit MO; Eladaoui A; Chang HH; Mapes J; Mogenet A; Bresson JL; Prié D; Béchet S; Baron C; Sadorge C; Thomas S; Albert EB; Albert PS; Albert ML
    J Urol; 2009 Apr; 181(4):1571-80. PubMed ID: 19230924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
    Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
    J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
    Ratliff TL; Palmer JO; McGarr JA; Brown EJ
    Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain.
    Kamat MR; Kulkarni JN; Tongaonkar HB; Dalal AV
    J Urol; 1994 Nov; 152(5 Pt 1):1424-8. PubMed ID: 7933175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
    J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer.
    van der Meijden PM; van Klingeren B; Steerenberg PA; de Boer LC; de Jong WH; Debruyne FM
    J Urol; 1991 Aug; 146(2):444-6. PubMed ID: 1856950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
    Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
    J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.
    Steg A; Leleu C; Debré B; Boccon-Gibod L; Sicard D
    Prog Clin Biol Res; 1989; 310():325-34. PubMed ID: 2672020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.